POTASSIUM ACETATE
Clinical safety rating
cautionComprehensive clinical and safety monograph for POTASSIUM ACETATE (POTASSIUM ACETATE).
Potassium acetate provides potassium ions, which are essential for maintaining intracellular ionic balance, nerve conduction, muscle contraction, and acid-base equilibrium. It acts as a potassium replenisher and can also be used to alkalinize urine by converting to bicarbonate.
| Metabolism | Potassium acetate is metabolized via the Krebs cycle to yield bicarbonate, primarily in the liver and kidneys, providing an alkalinizing effect. |
| Excretion | Primarily renal (>90%) as potassium ions; minimal biliary/fecal. |
| Half-life | Not applicable as potassium is not eliminated by first-order kinetics; plasma concentration reflects body stores and renal function. |
| Protein binding | Negligible (<5%); not significantly protein-bound. |
| Volume of Distribution | Approximately 0.5-0.7 L/kg; primarily intracellular distribution. |
| Bioavailability | Oral: 80-90% (absorbed from GI tract); intravenous: 100%. |
| Onset of Action | Intravenous: immediate upon infusion; oral: within 30-60 minutes. |
| Duration of Action | Duration depends on dose, administration rate, and renal function; typically 2-4 hours after IV bolus, longer with continuous infusion. |
| Molecular Weight | 98.14 |
Intravenous, 10-20 mEq/h, maximum infusion rate 20 mEq/h, not to exceed 150 mEq/day.
| Dosage form | INJECTABLE |
| Renal impairment | GFR 30-60 mL/min: consider 50% dose reduction; GFR <30 mL/min: contraindicated or use with extreme caution, monitor potassium levels closely. |
| Liver impairment | No specific adjustment recommended; monitor potassium levels due to risk of hyperkalemia in hepatic impairment. |
| Pediatric use | Intravenous, 0.5-1 mEq/kg/dose, maximum infusion rate 0.5 mEq/kg/h, not to exceed 3 mEq/kg/day. |
| Geriatric use | Start at lower end of adult dosing (10 mEq/h), monitor renal function and potassium levels, adjust according to renal function. |
| 1st trimester | Potassium acetate is essential for maternal and fetal electrolyte balance. Use only when clearly needed and if alternative therapies are inadequate. Monitor serum potassium closely to avoid hyperkalemia. |
| 2nd trimester | Same as first trimester. Maintain serum potassium within normal limits to prevent adverse fetal effects. |
| 3rd trimester | Same as first trimester. May be used to treat hypokalemia; close monitoring recommended due to risk of hyperkalemia in pregnancy. |
Clinical note
Comprehensive clinical and safety monograph for POTASSIUM ACETATE (POTASSIUM ACETATE).
| Placental transfer | Potassium freely crosses the placenta via active transport and diffusion. Fetal serum levels are regulated; excess potassium can lead to fetal hyperkalemia. |
| Breastfeeding | Potassium acetate is normal constituent of breast milk; supplementation does not significantly alter milk content. Excretion into milk is minimal. Use caution with high doses to avoid maternal hyperkalemia which may affect infant through milk. |
| Lactation Rating | L1 (Compatible) |
| Teratogenic Risk | Potassium acetate is an electrolyte used for potassium repletion. No specific teratogenic effects are documented; however, potassium imbalance (hyperkalemia or hypokalemia) may affect fetal cardiac function. Use during pregnancy requires careful monitoring to maintain maternal serum potassium within the normal range, as maternal hypokalemia or hyperkalemia can cause fetal arrhythmias or other complications. No trimester-specific risks are established. |
| Fetal Monitoring | Monitor maternal serum potassium levels frequently; monitor fetal heart rate and uterine activity during intravenous administration for preterm labor or fetal distress signs. If potassium is used for cardiac arrhythmias, continuous ECG monitoring is required. |
| Fertility Effects | No known negative effects on fertility. Potassium is essential for cellular function, and imbalances (hypo/hyperkalemia) may indirectly impair reproductive physiology, but no direct effects of potassium acetate on fertility are reported. |
■ FDA Black Box Warning
Potassium acetate injections should be diluted and administered slowly to avoid hyperkalemia and cardiac arrest. Rapid or concentrated infusion can be fatal.
| Serious Effects |
HyperkalemiaSevere renal impairment with oliguria or anuriaAddison's diseaseAcidosisConcomitant use with potassium-sparing diureticsAnuria
| Precautions | Risk of hyperkalemia, especially in renal impairment, Cardiac arrhythmias and arrest if administered too rapidly or in concentrated form, Use with caution in patients with cardiac disease, metabolic acidosis, or those receiving potassium-sparing diuretics, Monitor serum potassium, ECG, and renal function during therapy, Extravasation risk with peripheral IV administration |
| Food/Dietary | Avoid excessive intake of potassium-rich foods (e.g., bananas, oranges, tomatoes, potatoes, avocados, spinach, beans) and potassium-containing salt substitutes, especially during therapy, to prevent hyperkalemia. |
| Clinical Pearls | Potassium acetate is an intravenous electrolyte replenisher used for treating or preventing hypokalemia. It must be diluted before administration; the undiluted solution is highly irritating to veins. Maximum infusion rate should not exceed 10 mEq/h, and ECG monitoring is recommended during rapid replacement. Use with caution in renal impairment or conditions that predispose to hyperkalemia. Avoid potassium acetate in patients with digoxin toxicity unless severe hypokalemia is present. |
| Patient Advice | Report any signs of hyperkalemia such as muscle weakness, tingling, or irregular heartbeat. · Do not consume potassium-rich foods or salt substitutes while receiving this medication unless directed by your doctor. · Inform your healthcare provider if you have kidney problems, heart disease, or are taking ACE inhibitors, ARBs, or potassium-sparing diuretics. · IV administration may cause burning or pain at the infusion site; notify the nurse if this occurs. |
Loading safety data…